Finance

Transdermal drug delivery pharmaceutical reports third quarter EPS of $0.11

Published in Women's Health Weekly, December 9th, 2004

Noven Pharmaceuticals, Inc. (NOVN) announced financial results for the quarter and 9 months ended September 30, 2004, provided an update on its business, and confirmed prior financial guidance for full-year 2004.

"Third quarter results at our Novogyne joint venture reflect our continued leadership position in the transdermal hormone therapy ("HT") market," said Robert C. Strauss, Noven president, CEO and chairman.

Noven's net revenues for the quarter ended September 30, 2004 were $10.1 million, an 11% increase over the $9.1 million reported in the quarter ended September 30, 2003. Net revenues for the 2003 quarter reflected the establishment of a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2004-12-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry